Royalty Pharma publishes Q3 2026 earnings call transcript
RPRX•Royalty Pharma raised its 2026 Portfolio Receipts guidance to $3.5 billion–$3.55 billion from $3.4 billion–$3.5 billion, and lifted its Royalty Receipts growth forecast to 10%–11% from 7%–10%. Third-quarter Portfolio Receipts rose 9% to $890 million, and Portfolio Cash Flow was $673 million.
1. Guidance raised
Royalty Pharma raised its 2026 Portfolio Receipts guidance to $3.5 billion–$3.55 billion from $3.4 billion–$3.5 billion, marking its third consecutive quarterly increase. It now forecasts Royalty Receipts growth of 10%–11%, compared with 7%–10% previously, reflecting stronger portfolio momentum.
2. Quarterly results
Third-quarter Portfolio Receipts rose 9% to $890 million, while Portfolio Cash Flow reached $673 million. Despite pelacarsen’s Phase 3 failure, the Ionis agreement provides $550 million in Spinraza royalty payments, a 1.1-times return on funding.
